| Name | Title | Contact Details |
|---|
Reliable Controls manufactures simple, flexible, sustainable building automation solutions that balance comfort and efficiency while reducing greenhouse gas emissions in buildings around the world. Our goal to help others achieve their goals begins by listening. We hear the World Green Building Councils call to businesses, organizations, cities, states, and regions to reach net-zero operation by 2050. The next 30 years are critical. In the world of building automation systems, that means you want products that are built responsibly and built to last. Reliable Controls technology is backward compatible, better by design, and supported by responsible recycling. Install our controllers now, and they will thrive for decades. Thats a sustainable return on investment. This dedication to multigenerational success is unique to our brand and reflects our pledge to sustainability. Its with purpose that we refer to our lineup of controllers or sensors as a family; each generation adds value, and nothing is rendered obsolete. We also take great pride in creating a healthy, sustainable working environment for our employees—as evidenced in our Canadas Greenest Employer Award honors in 2020.
Search Discovery is a data strategy and activation company whose focus is helping you turn raw data into the right decisions. You get a smarter, more personalized approach across strategy, technology, and execution. Many companies like yours have been playing a guessing game when it comes to critical business decisions. Too often, you either dont know if you have the right data, dont know if you can trust it, or dont know exactly what to do with it. Its time to own the unknown, and only Search Discovery brings you this level of practical strategy, flexibility, and focus. Its also why so many of the worlds leading brands rely on us. And its how weve earned a client retention rate of over 90%. Search Discovery. Own the unknown.™ Search Discovery | Own the Unknown
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.